Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091273 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00091273: Completed Phase 1 study, sponsored by University of Virginia.
NCT00091273 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091273, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients with ovarian epithelial or primary peritoneal cancer.
Primary Outcome
Participants kept a toxicity diary during the time frame of interest which was reviewed with a study clinician at each visit.
Interventions
- PROCEDURE adjuvant therapy
- BIOLOGICAL sargramostim
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL tetanus toxoid helper peptide
- BIOLOGICAL ovarian cancer peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
What the finished NCT00091273 record still lists
NCT00091273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 5 interventions - of which adjuvant therapy is the first listed.
NCT00091273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00091273 about?
NCT00091273 is a clinical study titled "Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer". RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients with ovarian epithelial or primary peritoneal cancer.
What is the current status of trial NCT00091273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2004-06. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00091273?
The interventions under investigation include: adjuvant therapy (PROCEDURE), sargramostim (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), tetanus toxoid helper peptide (BIOLOGICAL), ovarian cancer peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00091273?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00091273's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia